Literature DB >> 19710242

Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions.

Sun Ha Lee1, Tae-Hyun Yoo, Bo-Young Nam, Dong Ki Kim, Jin Ji Li, Dong-Sub Jung, Seung-Jae Kwak, Dong-Ryeol Ryu, Seung Hyeok Han, Jung Eun Lee, Sung Jin Moon, Dae Suk Han, Shin-Wook Kang.   

Abstract

Previous studies have shown that mineralocorticoid receptor (MCR) blocker reduces proteinuria in diabetic nephropathy (DN), but the role of aldosterone in podocyte injury has never been explored in DN. This study was undertaken to elucidate whether a local aldosterone system existed in podocytes and to examine its role in podocyte apoptosis under diabetic conditions. In vitro, immortalized podocytes were exposed to 5.6 mM glucose (NG), NG + 24.4 mM mannitol, and 30 mM glucose (HG) with or without 10(-7) M spironolactone (SPR). In vivo, 32 Sprague-Dawley rats were injected with diluent (C, n = 16) or streptozotocin intraperitoneally [diabetes mellitus (DM), n = 16], and 8 rats from each group were treated with SPR for 3 mo. Aldosterone synthase (CYP11B2) and MCR mRNA and protein expression were determined by real-time PCR and Western blot, respectively, and aldosterone levels by radioimmunoassay. Western blot for apoptosis-related molecules, Hoechst 33342 staining, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay were performed to determine apoptosis. CYP11B2 and MCR expression were significantly higher in HG-stimulated podocytes and DM glomeruli compared with NG cells and C glomeruli, respectively, along with increased aldosterone levels. Western blot analysis revealed that cleaved caspase-3 and Bax expression was significantly increased, whereas Bcl-2 expression was significantly decreased in HG-stimulated podocytes and in DM glomeruli. Apoptosis determined by Hoechst 33342 staining and TUNEL assay were also significantly increased in podocytes under diabetic conditions. These changes in the expression of apoptosis-related proteins and the increase in apoptotic cells were inhibited by SPR treatment. These findings suggest that a local aldosterone system is activated and is involved in podocyte apoptosis under diabetic conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710242     DOI: 10.1152/ajprenal.00101.2009

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  18 in total

Review 1.  Endothelial dysfunction as a potential contributor in diabetic nephropathy.

Authors:  Takahiko Nakagawa; Katsuyuki Tanabe; Byron P Croker; Richard J Johnson; Maria B Grant; Tomoki Kosugi; Qiuhong Li
Journal:  Nat Rev Nephrol       Date:  2010-11-02       Impact factor: 28.314

2.  The role of aldosteronism in causing obesity-related cardiovascular risk.

Authors:  David A Calhoun; Kumar Sharma
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

Review 3.  Aldosterone blockade in chronic kidney disease: can it improve outcome?

Authors:  Robert D Toto
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-09       Impact factor: 2.894

Review 4.  Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.

Authors:  Helmy M Siragy; Robert M Carey
Journal:  Am J Nephrol       Date:  2010-05-18       Impact factor: 3.754

Review 5.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

Review 6.  Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.

Authors:  Nancy J Brown
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

Review 7.  Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.

Authors:  Stacy A Johnson; Robert F Spurney
Journal:  Am J Physiol Renal Physiol       Date:  2015-09-02

8.  Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease.

Authors:  Louis L Huang; David J Nikolic-Paterson; Yingjie Han; Elyce Ozols; Frank Y Ma; Morag J Young; Greg H Tesch
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

9.  Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.

Authors:  James M Luther; Pengcheng Luo; Zuofei Wang; Samuel E Cohen; Hyung-Suk Kim; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

10.  Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.

Authors:  Nobuaki Takagi; Takakuni Tanizawa; Valentina Kon; Agnes B Fogo; Iekuni Ichikawa; Ji Ma
Journal:  Nephron Extra       Date:  2012-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.